Habenbacher Michael, Moser Ulrich, Abaira Ahmed, Kiss Peter, Holzmeister Clemens, Pock Jakob, Walla Katharina, Lang Angelika, Andrianakis Alexandros
Department of Otorhinolaryngology, Medical University of Graz, Graz, Austria.
Eur Arch Otorhinolaryngol. 2025 Jun;282(6):3329-3334. doi: 10.1007/s00405-025-09275-2. Epub 2025 Feb 20.
This study aimed to investigate the impact of baseline nasal polyp score (NPS) on the effectiveness of dupilumab treatment in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
In this retrospective observational study, 80 CRSwNP patients treated with dupilumab 300 mg biweekly at a tertiary referral center were stratified according to the baseline NPS into two groups: low-NPS (< 5) and high-NPS (≥ 5). Treatment outcomes were evaluated at the 6-month follow-up visit and compared.
Both groups showed significant clinical improvements. The NPS decreased significantly in both low- and high-NPS groups, from a mean score of 3.2 to 0.8 and from 6.1 to 1.4, respectively (p < 0.001 for both). SNOT-22 scores improved significantly in both groups (p < 0.001 for both), though the reduction was greater in the high-NPS group (35.5 vs. 23.9, p = 0.018). There were no significant differences between low- and high NPS groups in proportions of NPS reduction of ≥ 1 (89% vs. 95%, p = 0.396) and clinically significant SNOT-22 improvement (= reduction > 12 or follow-up SNOT < 40; 80% vs. 86%, p = 0.544).
Our results suggests that dupilumab is effective in CRSwNP treatment, regardless of baseline nasal polyp size. Both small and large polyp groups showed significant improvements in NPS and patient-reported outcome measures. Future, prospective studies are warranted to validate these findings.
本研究旨在探讨基线鼻息肉评分（NPS）对度普利尤单抗治疗慢性鼻-鼻窦炎伴鼻息肉（CRSwNP）患者疗效的影响。
在这项回顾性观察研究中，在一家三级转诊中心接受每两周一次300mg度普利尤单抗治疗的80例CRSwNP患者根据基线NPS分为两组：低NPS组（<5）和高NPS组（≥5）。在6个月的随访时评估并比较治疗结果。
两组均显示出显著的临床改善。低NPS组和高NPS组的NPS均显著降低，平均评分分别从3.2降至0.8以及从6.1降至1.4（两组均p<0.001）。两组的SNOT-22评分均显著改善（两组均p<0.001），尽管高NPS组的降低幅度更大（35.5对23.9，p=0.018）。低NPS组和高NPS组在NPS降低≥1的比例（89%对95%，p=0.396）和临床上显著的SNOT-22改善（=降低>12或随访时SNOT<40；80%对86%，p=0.544）方面无显著差异。
我们的结果表明度普利尤单抗在CRSwNP治疗中有效，无论基线鼻息肉大小如何。小息肉组和大息肉组在NPS和患者报告的结局指标方面均显示出显著改善。未来需要进行前瞻性研究来验证这些发现。
